The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid

European Journal of Clinical Pharmacology

Volumn 63, Issue 7, 2007, Pages 633-639

  Donald, P R ^a   Parkin, D P ^a   Seifart, H I ^a   Schaaf, H S ^a   Van Helden, P D ^b   Werely, C J ^b   Sirgel, F A ^b   Venter, A ^b   Maritz, J S ^c  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

Author keywords

Early bactericidal activity; Isoniazid; N acetyltransferase 2; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD LEVEL; CONTROLLED STUDY; DRUG ACETYLATION; DRUG DOSE REDUCTION; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ACETYLATION; ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; ISONIAZID; MALE; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; TIME FACTORS; TUBERCULOSIS, PULMONARY;

EID: 34250362745     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0305-5     Document Type: Article

References (39)

1. Anonymous (1962) Isoniazid dosage. Tubercle 43:196-198
2. Bellman R (1983) Mathematical methods in medicine. Series in modern applied mathematics, vol 1. World Scientific, Singapore
3. Biehl JP (1957) Emergence of drug resistance as related to the dosage and metabolism of isoniazid. In: Transactions of 16th conference on the chemotherapy of tuberculosis. Veterans Administration Army Navy, Washington, DC, pp 108-113
4. Bönicke R, Reif W (1953) Enzymatische Inaktiviering von Isonikotinsaure hydrazide in menslichen und Tierschen Organismus. Arch Exp Pathol Pharmakol 220:321-333
5. Crofton J (1958) "Sputum conversion" and the metabolism of isoniazid. Am Rev Tuberc 77:869-871
6. Donald PR, Sirgel FA, Botha FJ et al (1997) The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 156:895-900
7. Donald PR, Sirgel FA, Venter A et al (2001) Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis. Scand J Infect Dis 33:466-469
8. Donald PR, Sirgel FA, Venter A et al (2002) The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 6:693-698
9. Donald PR, Sirgel FA, Venter A et al (2004) The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 39:1425-1430
10. East African Hospitals/British Medical Research Council (1960) Comparative trial of isoniazid in combination with thiacetazone or a substituted diphenylthioures (SU1906) or PAS on the treatment of acute pulmonary tuberculosis in East Africa. Tubercle 41:399-423
11. East African/British Medical Research Council (1963) Isoniazid with thiacetazone in the treatment of pulmonary tuberculosis in East Africa. Second investigation. Tubercle 44:301-333
12. East African/British Medical Research Council (1966) Isoniazid with thiacetazone in the treatment of pulmonary tuberculosis in East Africa. Fourth investigation. Tubercle 47:315-339
13. Ellard G (1984) The potential clinical significance of isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 65:211-227
14. Elmendorf D, Cawthon WU, Muschenheim C, McDermott W (1952) The absorption, distribution, excretion and short-term toxicity of isonicotinic acid hydrazide (Nydrazid) in man. Am Rev Tuberc 429-442
15. Harris HW (1959) Report on study 16: high dosage INH. In: Transactions of the 18th conference on the chemotherapy of tuberculosis. Veterans Administration Army Navy, Washington, DC, pp 70-76
16. Hiratsuka M, Kishikawa Y, Takekuma Y et al (2002) Genotyping of the N-acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 17:357-362
17. Hughes HB (1953) On the metabolic fate of isoniazid. J Pharmacol Exp Therap 109:444-454
18. Hughes HB, Biehl JP, Jones AP, Schmidt LH (1954) Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 70:266-273
19. Jindani A, Aber VR, Edwards EA, Mitchison DA (1980) The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121:939-949
20. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A et al (2005) Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49:1733-1738
21. Klee P (1952) Die Behandelung der Tuberkulose mit Neoteben (isonikotinsäuerhydrazid). Deutsche med Wchnschr 77:578-581
22. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 16:1215
23. Mitchell RS, Bell JC (1957) Clinical implications of isoniazid blood levels in pulmonary tuberculosis. New Eng J Med 257:1066-1070
24. Mitchison DA (1979) Basic mechanisms of chemotherapy. Chest 76(Suppl):771-781
25. Mitchison DA (1998) How drug resistance emerges as result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 2:10-15
26. Mount FW, Ferebee SH (1954) United States Public Health Service cooperative investigation of antimicrobial therapy of tuberculosis. Report on thirty-two-week observations on combinations of isoniazid, streptomycin and para-aminosalicylic acid. Am Rev Tuberc 70:521-526
27. Ohno M, Yamaguchi I, Yamamoto I et al (2000) Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:251-256
28. Parkin DP, Vandenplas S, Botha FJH et al (1997) Trimodality of isoniazid elimination. Phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155:1717-1722
29. Peloquin CA, Nita AT, Burman WJ et al (1996) Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30:919-925
30. R Development Core Team. R: 2006 A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org
31. Robitzek EH, Selikoff IJ (1952) Hydrazine derivatives of isonicotinic acid (Rimifon, Marsalid) in the treatment of active progressive caseous-pneumonic tuberculosis. Am Rev Tuberc 65:402-428
32. Russel WF, Kass I, Heaton AD, Dressler SH, Middlebrook G (1959) Combined drug treatment of tuberculosis. III Clinical application of the principles of appropriate and adequate chemotherapy to the treatment of pulmonary tuberculosis. J Clin Investigation 38:1366-1375
33. Seifart HI, Gent WI, Parkin DP, van Jaarsveld PP, Donald PR (1995) High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr [Br] 674:269-275
34. Selikoff IJ, Robitzek EH, Ornstein GG (1952) Treatment of pulmonary tuberculosis with hydrazine derivatives of isonicotinic acid. JAMA 150:973-980
35. Tuberculosis Chemotherapy Centre, Madras (1963) The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. Bull Wld Hlth Org 38:455-475
36. Tuberculosis Chemotherapy Committee of the Medical Research Council (1953) Isoniazid in the treatment of pulmonary tuberculosis. Br Med J 1:521-536
37. Weiner M, Burman W, Vernon A et al (2003) Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 167:1341-1347
38. Weiner M, Benator D, Burman W et al (2005) Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40:1481-1491
39. World Health Organization (2003) Standardized treatment regimen. In: Treatment of tuberculosis: guidelines for national programmes. WHO/CDS/TB/2003.313.Geneva. WHO.2003:37-38